历期数据
MarkdownHSA上市后警戒指南第 6 版
HSA uploaded Version 6 of the post-marketing vigilance guidance on 1 April 2026, revising scope, contact requirements, serious-adverse-event criteria, identifiable-patient examples, literature reports, lack-of-efficacy reports, clinical safety study reports and eCTD submission references guidance revision
- 统计期间
- Version 6 uploaded 1 April 2026
- 适用人群
- Companies responsible for post-marketing surveillance of therapeutic products and CTGTP in Singapore
- 分母口径
- Guidance scope; not a marketing-authorisation decision and not a declaration that every adverse event is reportable
- 地理范围
- 新加坡
记录详情
- 发布日期
- 2026-04-01
- 指标
- revision
- 来源版本
- HSA Guidance Version 6
日期表示本记录的统计期间与适用范围。核验日期并不代表规则目前已经生效。
资料来源
知识库资料截至 2026-11-22 · 知识库持续扩充中。发布数量表示现有内容,并不代表已覆盖新加坡的全部知识。
机器可读版本: JSON · sgobs.healthcare.hsa-post-marketing-vigilance-guidance-2026.revision